Browse > Article

Value of the Serum Thyroglobulin Level Alteration at the First High Dose Radioiodine Treatment in Patients with Differentiated Thyroid Carcinoma  

Nam, Hyun-Yeol (Department of Nuclear Medicine, Pusan National University Hospital)
Kim, In-Joo (Department of Nuclear Medicine, Pusan National University Hospital)
Kim, Yong-Ki (Department of Nuclear Medicine, Pusan National University Hospital)
Kim, Seong-Jang (Department of Nuclear Medicine, Pusan National University Hospital)
Jun, Sung-Min (Department of Nuclear Medicine, Pusan National University Hospital)
Kim, Bum-Soo (Department of Nuclear Medicine, Pusan National University Hospital)
Publication Information
Nuclear Medicine and Molecular Imaging / v.43, no.4, 2009 , pp. 294-300 More about this Journal
Abstract
Purpose: The purpose of this study was to evaluate if short-term serum thyroglobulin (Tg) elevation after radioiodine administration can predict successful radioiodine remnant ablation (RRA) and whether comparable RRA effectiveness is exhibited between a group administered with recombinant human thyrotropin (rhTSH) and a group experiencing thyroid hormone withdrawal (THW), in preparation for RRA. Materials and Methods: A retrospective chart review was performed on 39 patients in the rhTSH group and 46 patients in the THW group. They were treated for differentiated thyroid carcinoma by total or near total thyroidectomy, and referred for RRA between 2003 and 2006 (the rhTSH group) and between January and June of 2006 (the THW group). They were assessed for serum Tg levels just before I-131 administration (TgD0), reassessed 9 days later (TgD9), and again 6-12 months later. Results: RRA was successful in 64 (37 from the THW group and 27 from the rhTSH group) of the total 85 patients. The success rates of RRA had no statistically significant differences between the two groups. In both groups, TgD9/TgD0 values were significantly higher in the RRA success group (the rhTSH group; P = 0.03, the THW group; P = 0.04). By combining cutoff values of TgD0 and TgD9/TgD0, the successful RRA value was determined to be 96.7% (29/30) with TgD0$\leq$5.28 ng/mL and TgD9/TgD0>4.37 in both groups (the rhTSH group; 100% (16/16), the THW group; 92.9% (13/14)). Using logistic multivariate analysis, only TgD0 was independently associated with successful RRA. Conclusion: We may predict successful ablation by evaluating short-term serum Tg elevation after I-131 administration for RRA, in both rhTSH and THW patients.
Keywords
Thyroglobulin; radioiodine remnant ablation; differentiated thyroid carcinoma; recombinant human thyrotropin; thyroid hormone withdrawal;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Pacini F. Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006;91:926-32   DOI   ScienceOn
2 Torrens J, Burch HB. Serum thyroglobulin measurement: Utility in clinical practice. Endocrinol Metab Clin North Am 2001;30:1-34   DOI   ScienceOn
3 Lima N, Cavaliere H, Tomimori E, Knobel M, Medeiros-Neto G. Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer. J Endocrinol Invest 2002;25:110-5   DOI   PUBMED   ScienceOn
4 Cramp WA, Yatvin MB, Harms-Ringdahl M. Recent developments in the radiobiology of cellular membranes. Acta Oncol 1994;33:945-52   DOI   ScienceOn
5 Rosario PW, Purisch S. Does a highly sensitive thyroglobulin (Tg) assay change the clinical management of low-risk patients with thyroid cancer with Tg on T4 <1 ng/ml determined by traditional assays? Clin Endocrinol (Oxf) 2008;68:338-42   DOI   PUBMED   ScienceOn
6 Sugino K, Ito K, Takami H. Management of differentiated thyroid carcinoma with radioiodine and recombinant human TSH. Endocr J 2006;53:723-8   DOI   ScienceOn
7 Arslan N, Ilgan S, Serdengecti M, Ozguven MA, Bayhan H, Okuyucu K, et al. Post-surgical ablation of thyroid remnants with high-dose $^{131}$I in patients with differentiated thyroid carcinoma. Nucl Med Commun 2001;22:1021-7   DOI   ScienceOn
8 Dow KH, Ferrell BR, Anello C. Quality of life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 1997;7:613-9   DOI   ScienceOn
9 Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oven WJ, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2008;35:1941-59   DOI   ScienceOn
10 Robbins RJ, Robbins AK. Clinical review 156: recombinant human thyrotropin and thyroid cancer management. J Clin Endocrinol Metab 2003;88:1933-8   DOI   ScienceOn
11 Bernier MO, Morel O, Rodien P, Muratet JP, Giraud P, Rohmer V, et al. Prognostic value of an increase in the serum thyroglobulin level at the time of the first ablative radioiodine treatment in patients with differentiated thyroid cancer. Eur J Nucl Med Imaging 2005;32:1418-21   DOI   ScienceOn
12 Sweeney DC, Johnston GS. Radioiodine therapy tor thyroid cancer. Endocrinol Metab Clin North Am 1995;24:803-39
13 Schlumberger M, Pacini F, Wiersinga WM, Toft A, Smit JW, Sanchez Franco F, et al. Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice. Eur J Endocrinol 2004;151:539-48   DOI   ScienceOn
14 Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 1999;9:421-7   DOI   ScienceOn
15 Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy tor papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:1447-63   DOI   ScienceOn
16 Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab 2006;91:878-84   DOI   ScienceOn
17 Tuttle RM, Brokhin M, Omry G, Martorella AJ, Larson SM, Grewal RK, et al. Recombinant-human TSH-assisted radioactive iodine remnant ablation achieves short term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med 2008;49:764-70   DOI   ScienceOn
18 Karam M, Gianoukakis A, Feustel PJ, Cheema A, Postal ES, Cooper JA. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates. Nucl Med Commun 2003;24:489-95   DOI   ScienceOn
19 Giovanella L, Ceriani L, Ghelfo A, Keller F, Sacchi A, Maffioli M, et at. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures. Clin Chem Lab Med 2006;44:648-52   DOI   ScienceOn
20 Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein He. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004;89:3668-76   DOI   ScienceOn
21 Crevenna R, Zettinig G, Keilani M, Posch M, Schmidinger M, Pirich C, et al. Quality of life in patients with non-metastatic differentiated thyroid cancer under thyroxin supplementation therapy. Support Cancer Care 2003;11:597-603   DOI   ScienceOn
22 Toubeau M, Touzery C, Arveux P, Chaplain G, Vaillant G, Berriolo A, et al. Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after $^131}$I ablation therapy in patients with differentiated thyroid cancer. J Nucl Med 2004;45:988-94   ScienceOn
23 Ronga G, Filesi M, Ventroni G, Vestri AR, Signore A Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma. Eur J Nucl Med 1999;26:1448-52   DOI   ScienceOn
24 Botella-Carretero JI, Galan JM, Caballero C, Sancho J, Escobar-Morreale HF. Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma. Endocr Relat Cancer 2003;10:601-10   DOI   ScienceOn
25 Menzel C, Kranert WT, Dobert N, Diehl M, Fietz T, Harnscho N, et al. rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of $^{131}$I. J Nucl Med 2003;44:1065-8   ScienceOn
26 Lee HJ, Rha SY, Jo YS, Kim SM, Ku BJ, Shong M, et al. Predictive value of the preablation serum thyroglobulin level after thyroidectomy is combined with postablation $^{131}$I whole body scintigraphy for successful ablation in patients with differentiated thyroid carcinoma. Am J Clin Oncol 2007;30:63-8   DOI   ScienceOn